Piperine, the pungent compound from black pepper, is mainly valuable for one well-proven ability: helping the body absorb other compounds far better, most notably turmeric's curcumin. Paired with curcumin it modestly improves cholesterol and inflammation. Its main drawback is pushing certain prescription drug levels higher, sometimes dangerously. Direct health claims remain unproven in people. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Total cholesterol | < 200 mg/dL (optimal often < 180) | Tracks the main metabolic benefit of curcumin–piperine regimens |
| LDL cholesterol (LDL-C) | < 100 mg/dL (lower for higher-risk individuals) | Primary lipid endpoint improved in combination trials |
| High-sensitivity CRP (hs-CRP) | < 1.0 mg/L | Captures the anti-inflammatory effect of the regimen |
| ALT / AST (liver enzymes) | ALT < 25 U/L (men), < 20 U/L (women); AST similar | Safety marker for hepatic load and clearance capacity |
| Fasting glucose | 70–90 mg/dL | Monitors glycemic component when used in metabolic regimens |
| Interacting drug level (e.g., tacrolimus, phenytoin) | Drug-specific therapeutic window | Detects piperine-driven over-exposure of narrow-window drugs |
Cadence: For metabolic goals, re-check lipid and inflammation markers at ~8–12 weeks then every 6–12 months; for those on interacting drugs, check drug level within 1–2 weeks of adding or removing piperine and whenever the dose changes.